TW200800975A - New compounds 2 - Google Patents

New compounds 2

Info

Publication number: TW200800975A
Authority: TW; Taiwan
Prior art keywords: treating; new compounds; relates; combinations; preparation
Prior art date: 2006-03-03

Application number

TW096107304A

Other languages

English (en)

Inventor

Ramesh Chandra Gupta

Vikrant Vijaykumar Jagtap

Appaji Baburao Mandhare

Tim Perkins

Christer Westerlund

Original Assignee

Torrent Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-03

Filing date

2007-03-02

Publication date

2008-01-01

2007-03-02 Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd

2008-01-01 Publication of TW200800975A publication Critical patent/TW200800975A/zh

Links

150000001875 compounds Chemical class 0.000 title abstract 4
102000015427 Angiotensins Human genes 0.000 abstract 1
108010064733 Angiotensins Proteins 0.000 abstract 1
208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
102000002045 Endothelin Human genes 0.000 abstract 1
108050009340 Endothelin Proteins 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
208000033679 diabetic kidney disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008816 organ damage Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Immunology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW096107304A 2006-03-03 2007-03-02 New compounds 2 TW200800975A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US77885506P	2006-03-03	2006-03-03

Publications (1)

Publication Number	Publication Date
TW200800975A true TW200800975A (en)	2008-01-01

Family

ID=38459328

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW096107304A TW200800975A (en)	2006-03-03	2007-03-02	New compounds 2

Country Status (14)

Country	Link
US (1)	US20100010035A1 (zh)
EP (1)	EP1996588A4 (zh)
JP (1)	JP2009529005A (zh)
KR (1)	KR20080104052A (zh)
CN (1)	CN101437818A (zh)
AR (1)	AR059883A1 (zh)
AU (1)	AU2007221495B2 (zh)
BR (1)	BRPI0708507A2 (zh)
CA (1)	CA2644578A1 (zh)
MX (1)	MX2008011227A (zh)
RU (1)	RU2425833C2 (zh)
TW (1)	TW200800975A (zh)
WO (1)	WO2007100295A1 (zh)
ZA (1)	ZA200807382B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110034378A1 (en)	2008-01-25	2011-02-10	Chaitanya Dutt	Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
JPWO2009096198A1 (ja) *	2008-02-01	2011-05-26	一般社団法人ファルマＩｐ	新規ビアリール誘導体
WO2010055474A2 (en) *	2008-11-13	2010-05-20	Ariel-University Research And Development Company Ltd.	Antimicrobial compounds and compositions
WO2011031745A1 (en)	2009-09-09	2011-03-17	Achaogen, Inc.	Antibacterial fluoroquinolone analogs
CN101891735B (zh) *	2009-11-25	2012-07-18	北京理工大学	联苯磺胺异噁唑类化合物、合成方法及用途
FR2957079B1 (fr) *	2010-03-02	2012-07-27	Sanofi Aventis	Procede de synthese de derives de cetobenzofurane
FR2958290B1 (fr)	2010-03-30	2012-10-19	Sanofi Aventis	Procede de preparation de derives de sulfonamido-benzofurane
GB201008134D0 (en) *	2010-05-14	2010-06-30	Medical Res Council Technology	Compounds
HUP1000330A2 (en)	2010-06-18	2011-12-28	Sanofi Sa	Process for the preparation of dronedarone and the novel intermediates
HUP1100167A2 (en)	2011-03-29	2012-11-28	Sanofi Sa	Process for preparation of dronedarone by mesylation
HUP1100165A2 (en)	2011-03-29	2012-12-28	Sanofi Sa	Process for preparation of dronedarone by n-butylation
FR2983198B1 (fr)	2011-11-29	2013-11-15	Sanofi Sa	Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP2617718A1 (en)	2012-01-20	2013-07-24	Sanofi	Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
WO2013121235A2 (en)	2012-02-13	2013-08-22	Sanofi	Process for preparation of dronedarone by removal of hydroxyl group
US9249119B2 (en)	2012-02-14	2016-02-02	Sanofi	Process for the preparation of dronedarone by oxidation of a sulphenyl group
WO2013124745A1 (en)	2012-02-22	2013-08-29	Sanofi	Process for preparation of dronedarone by oxidation of a hydroxyl group
US9238636B2 (en)	2012-05-31	2016-01-19	Sanofi	Process for preparation of dronedarone by Grignard reaction
EA037041B1 (ru)	2015-04-08	2021-01-29	Торрент Фармасьютикалз Лимитед	Пероральные фармацевтические составы для лечения связанных с диабетом макрососудистых и микрососудистых осложнений
CN107438604B (zh)	2015-04-08	2021-12-03	托伦特药物有限公司	新吡啶化合物
CN105218388B (zh) *	2015-10-26	2017-07-11	西北农林科技大学	β‑羰基烯胺类化合物及作为制备植物病原菌抗菌剂的应用
US10858342B2 (en)	2016-06-28	2020-12-08	Boehringer Ingelheim International Gmbh	Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases
US11261184B2 (en)	2017-10-02	2022-03-01	Boehringer Ingelheim International Gmbh	[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors
EP3962903A1 (en)	2019-05-01	2022-03-09	Boehringer Ingelheim International GmbH	(r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CN112239507A (zh)	2019-07-17	2021-01-19	鸿运华宁（杭州）生物医药有限公司	ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
WO2022266370A1 (en)	2021-06-17	2022-12-22	Aria Pharmaceuticals, Inc.	Sparsentan for treating idiopathic pulmonary fibrosis
CN117836294A (zh) *	2021-08-26	2024-04-05	上海翰森生物医药科技有限公司	含芳环类生物拮抗剂、其制备方法和应用
JP2024178482A (ja) *	2021-11-15	2024-12-25	株式会社アークメディスン	化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
TW202339719A (zh)	2021-12-14	2023-10-16	德商百靈佳殷格翰國際股份有限公司	用於治療慢性腎臟病之醛固酮合成酶抑制劑
TW202423432A (zh) *	2022-11-11	2024-06-16	日商亞克醫藥股份有限公司	化合物、內皮素a受體拮抗劑、血管收縮素ii第一型受體拮抗劑及醫藥組合物
CN116675684B (zh) *	2023-08-02	2023-11-07	上海翰森生物医药科技有限公司	含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5594021A (en) *	1993-05-20	1997-01-14	Texas Biotechnology Corporation	Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) *	1987-09-25	1999-10-05	Texas Biotechnology Corporation	Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5411980A (en) *	1989-07-28	1995-05-02	Merck & Co., Inc.	Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5760038A (en) *	1995-02-06	1998-06-02	Bristol-Myers Squibb Company	Substituted biphenyl sulfonamide endothelin antagonists
UA58494C2 (uk) *	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5846990A (en) *	1995-07-24	1998-12-08	Bristol-Myers Squibb Co.	Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) *	1995-10-11	1997-05-13	Bristol Myers Squibb Co	置換ビフェニルスルホンアミドエンドセリン拮抗剤
CA2496680A1 (en) *	1997-04-28	1998-11-05	Encysive Pharmaceuticals Inc.	Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
DK1094816T3 (da) *	1998-07-06	2009-04-06	Bristol Myers Squibb Co	Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
US6638937B2 (en) *	1998-07-06	2003-10-28	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CA2395088A1 (en) *	1999-12-15	2001-06-21	Bristol-Myers Squibb Company	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

2007
- 2007-03-01 US US12/224,617 patent/US20100010035A1/en not_active Abandoned
- 2007-03-01 CN CNA2007800159088A patent/CN101437818A/zh active Pending
- 2007-03-01 KR KR1020087024448A patent/KR20080104052A/ko not_active Ceased
- 2007-03-01 CA CA002644578A patent/CA2644578A1/en not_active Abandoned
- 2007-03-01 WO PCT/SE2007/000199 patent/WO2007100295A1/en not_active Ceased
- 2007-03-01 AU AU2007221495A patent/AU2007221495B2/en not_active Expired - Fee Related
- 2007-03-01 EP EP07716024A patent/EP1996588A4/en not_active Withdrawn
- 2007-03-01 JP JP2008557236A patent/JP2009529005A/ja active Pending
- 2007-03-01 BR BRPI0708507-9A patent/BRPI0708507A2/pt not_active IP Right Cessation
- 2007-03-01 MX MX2008011227A patent/MX2008011227A/es not_active Application Discontinuation
- 2007-03-01 RU RU2008139321/04A patent/RU2425833C2/ru not_active IP Right Cessation
- 2007-03-02 TW TW096107304A patent/TW200800975A/zh unknown
- 2007-03-05 AR ARP070100905A patent/AR059883A1/es not_active Application Discontinuation
2008
- 2008-08-27 ZA ZA200807382A patent/ZA200807382B/xx unknown

Also Published As

Publication number	Publication date
AR059883A1 (es)	2008-05-07
RU2425833C2 (ru)	2011-08-10
AU2007221495B2 (en)	2011-09-15
CN101437818A (zh)	2009-05-20
ZA200807382B (en)	2009-04-29
EP1996588A1 (en)	2008-12-03
BRPI0708507A2 (pt)	2011-05-31
RU2008139321A (ru)	2010-04-10
CA2644578A1 (en)	2007-09-07
EP1996588A4 (en)	2011-10-05
JP2009529005A (ja)	2009-08-13
US20100010035A1 (en)	2010-01-14
WO2007100295A1 (en)	2007-09-07
MX2008011227A (es)	2009-02-10
KR20080104052A (ko)	2008-11-28
AU2007221495A1 (en)	2007-09-07

Publication	Publication Date	Title
TW200800975A (en)	2008-01-01	New compounds 2
IL258880A (en)	2018-06-28	Diarylhydantoin compounds
MX2009006195A (es)	2009-06-30	Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2009006627A (es)	2009-08-12	Quinazolinas para la inhibicion de pdk1.
MX361467B (es)	2018-12-06	Compuestos de isoindolina para uso en el tratamiento de cancer.
WO2009011850A3 (en)	2009-03-05	Novel therapeutic compounds
TW200736233A (en)	2007-10-01	Cyclohexyl piperazinyl methanone derivatives
TNSN08370A1 (en)	2009-12-29	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MY159491A (en)	2017-01-13	Disubstituted phthalazine hedgehog pathway antagonists
BRPI0908635A8 (pt)	2018-12-18	composto, composição farmacêutica e método de tratamento de câncer
MX2010004312A (es)	2010-07-05	Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
WO2008112290A3 (en)	2008-12-31	Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2010121164A3 (en)	2011-02-24	1,4-benzodiazepinone compounds and their use in treating cancer
TN2011000166A1 (en)	2012-12-17	Disubstituted phthalazine hedgehog pathway antagonists
MX2009012421A (es)	2009-12-01	Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2.
MX2010002667A (es)	2010-04-01	Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
WO2010075280A3 (en)	2010-08-19	Coumarin-based compounds for the treatment of alzheimer's disease and cancer
WO2010021934A3 (en)	2010-06-10	Azaindole inhibitors of iap
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
WO2007100920A3 (en)	2007-12-21	Diagnosis and treatment of prostate cancer
WO2008072952A3 (en)	2008-09-12	Anti-inflammatory compounds containing compositions for treatment of cancer
DE602008002598D1 (en)	2010-10-28	Cyclohexylderivate
WO2008057313A3 (en)	2008-11-27	Methods of using e2f2 for the treatment of hypertension
MX2010004314A (es)	2010-04-30	Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
MX2010004315A (es)	2010-07-06	Compuestos para inhibir la actividad de quinesina ksp.